Verona Pharma Plc (VRNA)

4.25
0.00 0.00
NASDAQ : Health Technology
Prev Close 4.25
Open 4.24
Day Low/High 4.24 / 4.25
52 Wk Low/High 3.65 / 13.38
Volume 1.66K
Avg Volume 3.70K
Exchange NASDAQ
Shares Outstanding 13.17M
Market Cap 64.92M
EPS -2.00
Div & Yield N.A. (N.A)

Latest News

Verona Pharma Reports Positive Top-Line Data From Phase 2a Trial With RPL554 In Cystic Fibrosis Patients

Verona Pharma Reports Positive Top-Line Data From Phase 2a Trial With RPL554 In Cystic Fibrosis Patients

RPL554 demonstrates a favorable pharmacokinetic and pharmacodynamic profile in cystic fibrosis patients

Verona Pharma Provides Clinical Development Update

Verona Pharma Provides Clinical Development Update

Accelerates top-line data readouts from ongoing clinical trials with RPL554 in COPD and CF

PDMR Dealing

PDMR Dealing

Verona Pharma Plc Operational Update And Financial Results For The Third Quarter Ended September 30, 2017

Verona Pharma Plc Operational Update And Financial Results For The Third Quarter Ended September 30, 2017

Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD

Verona Pharma Reports Positive Top-Line Data From U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose To Patients

Verona Pharma Reports Positive Top-Line Data From U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose To Patients

Earlier than expected results demonstrate absorption occurs primarily in the lungs following inhaled administration

PDMR Dealing

PDMR Dealing

Verona Pharma Doses First Patients In Phase 2b Clinical Trial Of RPL554 For COPD Maintenance Treatment

Verona Pharma Doses First Patients In Phase 2b Clinical Trial Of RPL554 For COPD Maintenance Treatment

Dose escalation trial will evaluate RPL554 in approximately 400 COPD patients

Verona Pharma Receives Regulatory Approval To Commence Phase 2b Clinical Trial Of RPL554 For COPD Maintenance Treatment In Five Countries Across Europe

Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients